Cepmox

Cepmox is an antibiotic from the penicillin group used to treat infections such as pneumonia, gonorrhea caused by E. coli, salmonella, etc.

Product dosage: 250mg
Package (num)	Per pill	Price	Buy
30	$1.37	$41.00 (0%)	🛒 Add to cart
60	$0.72	$82.00 $43.00 (48%)	🛒 Add to cart
90	$0.53	$123.00 $48.00 (61%)	🛒 Add to cart
120	$0.46	$164.00 $55.00 (66%)	🛒 Add to cart
180	$0.39	$246.00 $71.00 (71%)	🛒 Add to cart
270	$0.35	$369.00 $95.00 (74%)	🛒 Add to cart
360	$0.32 Best per pill	$492.00 $115.00 (77%)	🛒 Add to cart

Cepmox (amoxicillin/clavulanate potassium) is a potent, broad-spectrum beta-lactam/beta-lactamase inhibitor combination antibiotic engineered for the effective treatment of complex bacterial infections. It is specifically formulated to overcome bacterial resistance mechanisms, providing clinicians with a reliable therapeutic option for both community-acquired and hospital-onset infections. Its dual-action mechanism ensures comprehensive antimicrobial coverage, making it a cornerstone in empiric and directed therapy protocols across multiple clinical settings.

Features

• Active Ingredients: Amoxicillin 875 mg / Clavulanate potassium 125 mg per tablet
• Pharmacological Class: Penicillin-class beta-lactam antibiotic + beta-lactamase inhibitor
• Formulation: Film-coated tablets for oral administration
• Mechanism: Amoxicillin inhibits bacterial cell wall synthesis; clavulanate inhibits beta-lactamase enzymes
• Spectrum: Effective against Gram-positive (e.g., Staphylococcus aureus, Streptococcus pneumoniae) and Gram-negative bacteria (e.g., E. coli, Klebsiella spp., Haemophilus influenzae), including beta-lactamase-producing strains
• Bioavailability: Approximately 70% oral absorption, unaffected by food
• Half-life: ~1–1.5 hours; excreted renally

Benefits

• Superior Bacterial Eradication: Combats resistant pathogens through synergistic amoxicillin-clavulanate activity, reducing treatment failure rates.
• Reduced Hospitalization Need: Effective outpatient management of moderate-to-severe infections, decreasing healthcare burden.
• Broad Clinical Utility: Indicated for respiratory, skin/soft tissue, genitourinary, and intra-abdominal infections.
• Proven Safety Profile: Extensive clinical use with well-documented efficacy and tolerability.
• Flexible Dosing: BID (twice-daily) regimen enhances patient adherence compared to TID alternatives.
• Cost-Effective Therapy: Generic availability ensures accessibility without compromising quality.

Common use

Cepmox is routinely prescribed for bacterial infections where beta-lactamase-producing organisms are suspected or confirmed. Common indications include:

• Community-acquired pneumonia (excluding atypical pathogens)
• Acute bacterial sinusitis
• Otitis media
• Skin and skin structure infections (e.g., cellulitis, abscesses)
• Complicated and uncomplicated urinary tract infections
• Animal/human bite wounds
• Dental infections with systemic involvement
• Prophylaxis in contaminated surgery (off-label)

Dosage and direction

Standard Adult Dose: One tablet (amoxicillin 875 mg/clavulanate 125 mg) orally every 12 hours. Severe Infections/Low MIC Pathogens: May require 1 tablet every 8 hours. Renal Impairment: Adjust for CrCl <30 mL/min: 1 tablet every 12–24 hours. Duration: Typically 7–14 days based on infection severity and clinical response. Administration: Take with food to minimize gastrointestinal upset and enhance absorption.

Precautions

• Use with caution in patients with hepatic dysfunction (monitor LFTs).
• May cause antibiotic-associated colitis; discontinue if diarrhea develops.
• Prolonged use can result in fungal or bacterial superinfection.
• Not recommended for monotherapy in MRSA infections.
• Use in pregnancy only if clearly needed (Category B).
• Renal function should be assessed before and during prolonged therapy.

Contraindications

• History of hypersensitivity to amoxicillin, clavulanate, or other beta-lactam antibiotics.
• Previous history of cholestatic jaundice/hepatic dysfunction with Cepmox.
• Patients with infectious mononucleosis (high rash incidence).
• Concomitant use with disulfiram or alcohol (due to clavulanate).

Possible side effect

Common (>1%):

• Diarrhea/loose stools
• Nausea, vomiting
• Skin rash, urticaria
• Vaginal candidiasis

Less common (<1%):

• Reversible hepatitis, cholestatic jaundice
• Antibiotic-associated colitis (C. difficile)
• Headache, dizziness
• Reversible leukopenia/neutropenia
• Crystalluria (ensure hydration)

Drug interaction

• Probenecid: Decreases renal excretion of amoxicillin, increasing serum levels.
• Oral Contraceptives: May reduce efficacy; advise alternative contraception.
• Warfarin: Potential increased INR; monitor coagulation parameters.
• Allopurinol: Increased incidence of skin rash.
• Methotrexate: Reduced renal clearance may increase toxicity.

Missed dose

Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double the dose to catch up. Maintain regular scheduling to ensure constant therapeutic levels.

Overdose

Symptoms may include gastrointestinal distress (nausea, vomiting, diarrhea), electrolyte imbalances, or crystaluria. Management is supportive; hemodialysis may enhance elimination. No specific antidote exists.

Storage

Store at controlled room temperature (20–25°C). Keep in original container, away from moisture and light. Keep out of reach of children. Do not use after expiration date.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis and individualized treatment recommendations. Do not self-prescribe or share medication.

Reviews

Clinical Evidence: Meta-analyses confirm >85% clinical cure rates in respiratory and skin infections. Superior to amoxicillin monotherapy in beta-lactamase-positive infections. Physician Feedback: Valued for reliability in empiric therapy, though GI side effects are noted in 10–15% of patients. Patient Reports: Generally positive outcomes; adherence aided by BID dosing. Some report nausea manageable with food.